Altimmune (ALT) acquired Spitfire Pharma in a deal that could ultimately be worth up to $93 million. Some highlights of the deal include: Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of...